NHS GPs to Receive Extra Payments for Prescribing Weight Loss Jabs
In a major shift for the National Health Service, general practitioners across the United Kingdom are now being financially incentivised to identify and prescribe weight loss injections to patients most in need. This initiative is part of a new GP contract that includes a dedicated £25 million funding pot, designed to support the rollout of appetite-suppressing drugs alongside comprehensive weight management programmes.
Addressing the Prescription Gap
Currently, an estimated 2.4 million Britons are using weight loss jabs such as Mounjaro and Wegovy. However, the vast majority of these individuals have been forced to pay privately for their treatments due to limited NHS availability. Health Secretary Wes Streeting emphasised the government's commitment to fairness, stating, "Weight-loss drugs can be a real game changer for those who need them. I'm determined that access should be based on need, not ability to pay."
He further highlighted concerns about the private market, noting the proliferation of unlicensed drugs and rogue prescribers that pose significant risks to patients. The new incentives aim to bring these treatments under the NHS umbrella, ensuring safer and more equitable access.
How the Jabs Work and Their Impact
Weekly injections like Ozempic, Wegovy, and Mounjaro function by mimicking the hormone glucagon-like peptide 1 (GLP-1), which regulates hunger and promotes feelings of fullness. This mechanism slows digestion and reduces appetite, leading to substantial weight loss. Clinical trials have shown particularly impressive results with Mounjaro, where participants lost an average of 26% of their body weight over 18 months.
However, these medications are not standalone solutions. They must be accompanied by personalised diet and lifestyle coaching, including regular exercise, to prevent muscle loss and ensure long-term success. Without these supportive measures, patients risk regaining the weight.
Challenges and Criticisms
The rollout faces significant hurdles. Health leaders have warned that if all eligible patients—estimated at over three million—sought treatment in the first year, it could overwhelm primary care services. NHS England projects that managing this demand could consume up to one in five GP appointments, a daunting prospect for already overstretched practices.
Henry Gregg, chief executive of the National Pharmacy Association, advocates for a broader approach. "The NHS roll out of weight loss treatments remains very slow and only a handful of patients are being treated," he said. "The Government should make better use of pharmacies to prescribe the jabs rather than relying on overstretched GPs."
Additionally, an investigation by the British Medical Journal revealed that despite the fanfare surrounding the 2024 announcement of Mounjaro's NHS rollout, funding for the first year covered only 10% of the required doses. With 3.4 million people technically eligible, the NHS has planned a phased implementation over 12 years, raising concerns about accessibility and timing.
Looking Ahead
The Obesity Health Alliance, a coalition of 60 health charities and medical organisations, has cautioned that the NHS currently lacks the capacity to expand the rollout of these "life-changing" injections effectively. As the government moves forward with its incentivised programme, the focus will be on ensuring that the phased approach prioritises those with the highest clinical need while building sustainable support systems for long-term patient health.
